The diagnosis of dyslipidemia is increasing both in adulthood and in childhood because of not only the steadily increasing prevalence of obesity but also a rise of medical attention in detecting unfavorable genetic conditions in patients of all ages. Attempts in lifestyle changes are frequently failing and thus the pharmacological treatment of dyslipidemia is spreading in medical practice to reduce cardiovascular risk. In childhood, statins are authorized by 8 years of age. Nevertheless, data on their long-term safety and efficacy are still lacking, especially in ones with high cardiovascular risk and/or primary dyslipidemia such as homozygous familial hypercholesterolemia, considerable as a mainly exclusively pediatric disease. Thus, new pharmacological approaches are needed and have to be evaluated in all categories of patients. In this context, the update and the critical revision of new medications have become a new duty for scientists and clinicians.

Novel insights on the treatment of hypercholesterolemia / Iughetti, Lorenzo; Predieri, Barbara; Bruzzi, Patrizia. - In: EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM. - ISSN 1744-6651. - STAMPA. - 10:3(2015), pp. 269-271. [10.1586/17446651.2015.1033373]

Novel insights on the treatment of hypercholesterolemia

IUGHETTI, Lorenzo;PREDIERI, Barbara;BRUZZI, Patrizia
2015

Abstract

The diagnosis of dyslipidemia is increasing both in adulthood and in childhood because of not only the steadily increasing prevalence of obesity but also a rise of medical attention in detecting unfavorable genetic conditions in patients of all ages. Attempts in lifestyle changes are frequently failing and thus the pharmacological treatment of dyslipidemia is spreading in medical practice to reduce cardiovascular risk. In childhood, statins are authorized by 8 years of age. Nevertheless, data on their long-term safety and efficacy are still lacking, especially in ones with high cardiovascular risk and/or primary dyslipidemia such as homozygous familial hypercholesterolemia, considerable as a mainly exclusively pediatric disease. Thus, new pharmacological approaches are needed and have to be evaluated in all categories of patients. In this context, the update and the critical revision of new medications have become a new duty for scientists and clinicians.
2015
6-apr-2015
10
3
269
271
Novel insights on the treatment of hypercholesterolemia / Iughetti, Lorenzo; Predieri, Barbara; Bruzzi, Patrizia. - In: EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM. - ISSN 1744-6651. - STAMPA. - 10:3(2015), pp. 269-271. [10.1586/17446651.2015.1033373]
Iughetti, Lorenzo; Predieri, Barbara; Bruzzi, Patrizia
File in questo prodotto:
File Dimensione Formato  
Manuscript pre print.doc

Open access

Tipologia: Versione originale dell'autore proposta per la pubblicazione
Dimensione 63.5 kB
Formato Microsoft Word
63.5 kB Microsoft Word Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1070757
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 1
social impact